Polygenic architecture informs potential vulnerability to drug-induced liver injury

Journal: Nature Medicine

Published: 2020-09-07

DOI: 10.1038/s41591-020-1023-0

Affiliations: 13

Authors: 14

Go to article
Institutions Share
Takeda-CiRA Joint Program (T-CiRA), Japan 0.25
Takeda Pharmaceutical Company Limited, Japan 0.24
Yokohama City University (YCU), Japan 0.12
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA) 0.07
NIHR Nottingham Respiratory Biomedical Research Centre (BRU), United Kingdom (UK) 0.07
Newcastle University, United Kingdom (UK) 0.07
The University of North Carolina at Chapel Hill (UNC), United States of America (USA) 0.07
Takeda Pharmaceuticals U.S.A., Inc., United States of America (USA) 0.07
Cincinnati Children's Hospital Medical Center (CCHMC), United States of America (USA) 0.03
Tokyo Medical and Dental University (TMDU), Japan 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER